Effectiveness and Safety of Avatrombopag in Liver Cancer Patients with Severe Thrombocytopenia: Real-World Data and Challenges

BACKGROUND: Avatrombopag has been approved in patients who have severe thrombocytopenia (<50 × 10(9)/L) and chronic liver disease (CLD) while receiving invasive procedures. The real-world application and effectiveness of avatrombopag in the subgroup patients with liver cancer remain unknown. METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Ao, Chen, Jia-Feng, Wu, Jian-Zhang, Gao, Zheng, Shi, Ying-Hong, Fu, Xiu-Tao, Zhang, Xin, Liu, Wei-Ren, Gao, Qiang, Sun, Hui-Chuan, Shi, Guo-Ming, Fan, Jia, Ding, Zhen-Bin, Zhou, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668468/
https://www.ncbi.nlm.nih.gov/pubmed/36405248
http://dx.doi.org/10.1155/2022/9138195

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668468/
https://www.ncbi.nlm.nih.gov/pubmed/36405248
http://dx.doi.org/10.1155/2022/9138195

Ejemplares similares